Acalabrutinib added to bendamustine and rituximab decreased disease progression or death risks compared with BR and a placebo for mantle cell lymphoma.
An AI algorithm called "Sturgeon" can classify CNS tumours fast and accurately during surgery. This enables resection strategies adapted to tumour types.
Belantamab mafodotin plus pomalidomide and dexamethasone PVd for progression-free survival in participants with relapsed or refractory multiple myeloma.
High-risk diffuse large B-cell lymphoma patients with a complete metabolic response (CMR) after R-CHOP benefitted from atezolizumab consolidation therapy.
All-Trans Retinoic Acid plus Arsenic Trioxide was superior to ATRA-chemotherapy in event-free survival high-risk acute promyelocytic leukaemia.
Future hepatologists could have numerous drugs for MASLD control and treatment. Promising results from recent trials were presented at EASL 2024.
During EASL 2024, the rise of AI in radiology and liver pathology; and of multisystem / multiscale integration in HCC patient care was discussed.
AI is revolutionizing many fields, including hepatology. During EASL 2024, its clinical application was discussed, with a focus on personalized patient management.
Which diagnostic and treatment pathways for MASLD patients will exist in 2030? Dr. Ian Rowe discusses patient management scenarios in the near future.
A symposium addressed chronic viral hepatitis management in children, and whether all children with chronic viral hepatitis should be treated.
Liver diseases expert Prof. Umberto Vespasiani-Gentilucci addresses important innovations in disease management with a focus on PBC and ‘real world’ data use.
Physician and medical historian Dr Lea Münch looked into psychiatric patients' treatment during the Nazi occupation of Alsace, from the patients' point of view.
AML reveals a complex interplay between malignant cells and their environment where disease progression and treatment response is orchestrated.
The journey to unravelling the complexities of AML treatment, especially in intermediate-risk patients, evolves as novel diagnositcs and therapies are embraced.
Besides WHO's classification, ICC's system for AML diagnosis and treatment is also available since 2022. How do they differ and which should be followed?
A type 2 diabetes drug slowed the progression of Parkinson's disease symptoms, according to a French study testing lixisenatide effects on 156 patients.
A new study showed that VR provided greater pain relief than control in adult patients with moderate-to-severe pain related to cancer and its therapies.
The standard treatment for scabies is permethrin, but it is becoming less due to mutations in the scabies mite that have led to resistance development.
Some Crohn's disease or ulcerative colitis patients do not respond to infliximab or its effect diminish for them. This could be related to visceral fat mass.
BRCA1 and BRCA2 mutations are crucial in hereditary breast and ovarian cancer treatment and prevention. Finding suitable germline-analysis patients is hard.